Los #fitocannabinoides o #cannabinoides son los compuestos esenciales de la planta #Cannabis #Sativa L., popularmente conocida como #marihuana o #cáñamo. Descubre todos sus beneficios en este #informe riguroso.
Sígueme en instagram: https://www.instagram.com/aldo.garciaramos/
FUENTES DE INFORMACIÓN.
LIBROS:
– De la Fuente et al. Marihuana y Salud. (p. 24).
– Bouso, J. Cannabis Medicinal, de droga prohibida a solución terapéutica (2019) (p. 32).
– Conrad, C. Cannabis para la salud. (p.25)
ARTÍCULOS CIENTÍFICOS E INFORMES:
– Guía básica sobre los cannabinoides. Sociedad Española de Investigación sobre Cannabinoides. (SEIC) (2002) (p.13)
– Fisar, Z. (2009). Phytocannabinoids and endocannabinoids. Current drug abuse reviews, 2(1), 51-75.
– Ligresti, A. (2006). Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma. Journal of Pharmacology and Experimental Therapeutics, 318(3), 1375–1387.
– Carroll, C. B., Zeissler, M.-L., Hanemann, C. O., & Zajicek, J. P. (2012). Δ9-tetrahydrocannabinol (Δ9-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson’s disease. Neuropathology and Applied Neurobiology, 38(6), 535–547.
– Blaskovich, M.A.T., Kavanagh, A.M., Elliott, A.G. et al. The antimicrobial potential of cannabidiol. Commun Biol 4, 7 (2021). https://doi.org/10.1038/s42003-020-01530-y
– Kessler, Felix H. et al. Cannabidiol and mental health: possibilities, uncertainties, and controversies for addiction treatment. Brazilian Journal of Psychiatry [online]. 2021, v. 43, n. 5 [Accessed 3 August 2022], pp. 455-457
– McGuire et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. Am J Psychiatry. 2018 Mar 1;175(3):225-231.
– Prud’homme M, Cata R, Jutras-Aswad D. Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Subst Abuse. 2015 May 21; 9:33-8.
– Karler, R., Cely, W., & Turkanis, S. A. (1973). The anticonvulsant activity of cannabidiol and cannabinol. Life Sciences, 13(11), 1527–1531.
– Nachnani, R., Raup-Konsavage, W. M., & Vrana, K. E. (2020). The Pharmacological Case for Cannabigerol. Journal of Pharmacology and Experimental Therapeutics, 376(2), 204–212.
– Tomko AM, Whynot EG, Ellis LD, Dupré DJ. Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis. Cancers (Basel). 2020 jul 21;12(7):1985.
– Wirth, P. W., Sue Watson, E., ElSohly, M., Turner, C. E., & Murphy, J. C. (1980). Anti-inflammatory properties of cannabichromene. Life Sciences, 26(23), 1991–1995.
– ZAGOŽEN, M., ČERENAK, A. i KREFT, S. (2021). Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharmaceutica, 71 (3), 355-364.
– Furr, M., & Mahlberg, P. G. (1981). Histochemical Analyses of Laticifers and Glandular Trichomes in Cannabis sativa. Journal of Natural Products, 44(2), 153–159.
– Ángeles, G; Brindis, F; Cristians, S & Ventura, R. (2014). Cannabis sativa L., una planta singular. Revista mexicana de ciencias farmacéuticas, 45(4), 1-6.
– Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011 Aug;163(7):1344-64.
0:00 INICIO
0:44 LOS CANNABINOIDES
1:56 EL THC
3:45 EL CBD
6:37 CANNABINOL (CBN)
6:59 CANNABIGEROL (CBG)
7:39 CANNABICROMENO (CBC)
8:09 LOS TRICOMAS
8:41 OTROS CANNABINOIDES
9:07 TERPENOIDES Y FLAVONOIDES
9:57 RESUMEN
11:01 SISTEMA ENDOCANNABINOIDE
source
